Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane

TRAIL has been extensively explored as a cancer drug based on its tumor-selective activity profile but it is incapable per se of discriminating between death receptors expressed by normal host cells and transformed cancer cells. Furthermore, it is well documented that surface tethering substantially...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Yang, Tatzel, Katharina, Wang, Xuejun, Belt, Brian, Binder, Pratibha, Kuroki, Lindsay, Powell, Matthew A., Mutch, David G., Hawkins, William G., Spitzer, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058776/
https://www.ncbi.nlm.nih.gov/pubmed/27120790
http://dx.doi.org/10.18632/oncotarget.8925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058776/
https://www.ncbi.nlm.nih.gov/pubmed/27120790
http://dx.doi.org/10.18632/oncotarget.8925

Ejemplares similares